Skip to main content

Market Overview

I-Mab To Start Testing Alzheimer's Candidate In Human Trials

Share:
I-Mab To Start Testing Alzheimer's Candidate In Human Trials
  • The FDA has signed off I-Mab (NASDAQ: IMAB) Investigational New Drug (IND) application for Protollin, an Alzheimer's candidate.
  • Brigham and Women's Hospital and Inspirevax granted I-Mab and Nhwa global exclusive licenses to develop, manufacture, and commercialize Protollin.
  • Inspirevax will manufacture and supply Protollin for preclinical and clinical studies until the recruitment of the first patient in the Phase 1b MAD study. 
  • I-Mab will develop and commercialize Protollin outside of the Greater China territory, while Nhwa will develop and commercialize the drug in mainland China, Hong Kong, Macau, and Taiwan.
  • Price Action: IMAB shares are down 1.51% at $73.45 during the market session on the last check Friday.
  • Related content: Benzinga's Full FDA Calendar.
 

Related Articles (IMAB)

View Comments and Join the Discussion!

Posted-In: Alzheimer's disease Briefs Investigational New Drug ApplicationBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com